- Home
- CLB vs YMAB Comparison
CLB vs YMAB Comparison
Compare CLB & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLB
- YMAB
- Stock Information
- Founded
- CLB 1936
- YMAB 2015
- Country
- CLB United States
- YMAB United States
- Employees
- CLB N/A
- YMAB N/A
- Industry
- CLB
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CLB
- YMAB Health Care
- Exchange
- CLB Nasdaq
- YMAB Nasdaq
- Market Cap
- CLB 482.5M
- YMAB 386.7M
- IPO Year
- CLB 1995
- YMAB 2018
- Fundamental
- Price
- CLB $11.16
- YMAB $8.53
- Analyst Decision
- CLB Hold
- YMAB Buy
- Analyst Count
- CLB 2
- YMAB 10
- Target Price
- CLB $12.50
- YMAB $13.91
- AVG Volume (30 Days)
- CLB 450.4K
- YMAB 2.0M
- Earning Date
- CLB 07-23-2025
- YMAB 08-08-2025
- Dividend Yield
- CLB 0.36%
- YMAB N/A
- EPS Growth
- CLB 23.99
- YMAB N/A
- EPS
- CLB 0.62
- YMAB N/A
- Revenue
- CLB $517,378,000.00
- YMAB $85,385,000.00
- Revenue This Year
- CLB N/A
- YMAB N/A
- Revenue Next Year
- CLB $2.24
- YMAB $13.97
- P/E Ratio
- CLB $17.96
- YMAB N/A
- Revenue Growth
- CLB 0.70
- YMAB N/A
- 52 Week Low
- CLB $9.72
- YMAB $3.55
- 52 Week High
- CLB $21.83
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- CLB 52.96
- YMAB 81.62
- Support Level
- CLB $10.15
- YMAB $8.50
- Resistance Level
- CLB $10.72
- YMAB $8.54
- Average True Range (ATR)
- CLB 0.45
- YMAB 0.02
- MACD
- CLB 0.09
- YMAB 0.00
- Stochastic Oscillator
- CLB 97.30
- YMAB 80.00
About CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.